Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by RDA Financial Network

RDA Financial Network boosted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 17.2% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 8,419 shares of the pharmaceutical company’s stock after buying an additional 1,236 shares during the period. Vertex Pharmaceuticals comprises 0.9% of RDA Financial Network’s portfolio, making the stock its 27th biggest holding. RDA Financial Network’s holdings in Vertex Pharmaceuticals were worth $4,182,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Motiv8 Investments LLC purchased a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth approximately $26,000. Swiss RE Ltd. purchased a new position in Vertex Pharmaceuticals in the 4th quarter valued at $28,000. Eagle Bay Advisors LLC acquired a new stake in Vertex Pharmaceuticals during the 4th quarter worth $29,000. IMG Wealth Management Inc. grew its holdings in shares of Vertex Pharmaceuticals by 277.8% during the fourth quarter. IMG Wealth Management Inc. now owns 68 shares of the pharmaceutical company’s stock worth $31,000 after buying an additional 50 shares in the last quarter. Finally, Ares Financial Consulting LLC acquired a new stake in shares of Vertex Pharmaceuticals in the fourth quarter valued at about $33,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Key Headlines Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Second-quarter revenue rose 12.5% year over year to approximately $3.33 billion, exceeding Wall Street expectations. Growth was supported by continued demand for Vertex’s cystic fibrosis medicines, as well as contributions from sickle-cell disease, beta thalassemia and acute-pain treatments. Vertex Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Vertex raised its full-year 2026 revenue outlook to $13.1 billion-$13.2 billion, above the roughly $13.0 billion analyst consensus. The higher forecast reflects sustained strength in cystic fibrosis drug sales. Vertex raises annual revenue forecast
• Positive Sentiment: Profitability remained strong, with a 35.5% net margin and operating cash flow of approximately $1.4 billion. Vertex also highlighted strong growth from CASGEVY, its gene-edited therapy developed with CRISPR Therapeutics, and its expanding non-cystic-fibrosis pipeline.
• Neutral Sentiment: Vertex announced an agreement to acquire Crinetics Pharmaceuticals for approximately $10.0 billion in equity value, or about $8.8 billion net of estimated cash. The transaction would add PALSONIFY (paltusotine) and establish rare endocrine diseases as another major business area, but its scale may increase near-term execution and valuation risk. Crinetics acquisition announcement
• Negative Sentiment: Adjusted EPS was $4.73, narrowly below the $4.74 consensus; another data provider cited a $4.79 estimate. The modest miss likely drove the negative reaction despite revenue outperforming expectations and EPS increasing from $4.52 a year earlier. Vertex Pharmaceuticals Q2 Earnings Lag Estimates

Vertex Pharmaceuticals Trading Down 1.3%

Shares of VRTX opened at $470.72 on Tuesday. Vertex Pharmaceuticals Incorporated has a 12-month low of $362.50 and a 12-month high of $533.67. The firm has a 50-day moving average price of $471.34 and a 200 day moving average price of $460.44. The firm has a market capitalization of $119.47 billion, a P/E ratio of 27.92, a P/E/G ratio of 2.15 and a beta of 0.30.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, August 3rd. The pharmaceutical company reported $4.73 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.74 by ($0.01). Vertex Pharmaceuticals had a return on equity of 23.86% and a net margin of 35.51%.The firm had revenue of $3.33 billion for the quarter, compared to analyst estimates of $3.23 billion. During the same quarter in the previous year, the business posted $4.52 earnings per share. Vertex Pharmaceuticals’s revenue for the quarter was up 12.5% on a year-over-year basis. Equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 17.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

VRTX has been the topic of several research reports. Weiss Ratings raised shares of Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, July 17th. Morgan Stanley increased their price objective on shares of Vertex Pharmaceuticals from $612.00 to $616.00 and gave the company an “overweight” rating in a report on Tuesday, May 5th. Canaccord Genuity Group decreased their target price on shares of Vertex Pharmaceuticals from $437.00 to $436.00 and set a “hold” rating on the stock in a research note on Tuesday, May 5th. Truist Financial boosted their target price on Vertex Pharmaceuticals from $542.00 to $560.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Finally, Wall Street Zen lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, June 28th. Twenty-two equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $559.61.

Insider Transactions at Vertex Pharmaceuticals

In related news, EVP Ourania Tatsis sold 1,500 shares of the stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $524.99, for a total value of $787,485.00. Following the completion of the transaction, the executive vice president directly owned 45,321 shares in the company, valued at approximately $23,793,071.79. This represents a 3.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Carmen Bozic sold 596 shares of the firm’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $482.50, for a total value of $287,570.00. Following the sale, the chief marketing officer directly owned 15,337 shares of the company’s stock, valued at approximately $7,400,102.50. This trade represents a 3.74% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 17,452 shares of company stock worth $8,103,997 in the last 90 days. Insiders own 0.20% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.